RareCyte has raised USD 20 million in a venture funding round that included Forest Road, Arboretum Ventures, F-Prime Capital, HealthQuest Capital, 5AM Ventures, and Agilent Technologies.
The company plans to use the funds to expand RareCyte's primary platform, Orion Spatial Biology, which includes commercializing new multiplex assays, reagent products, and software applications. The funds will also enhance RareCyte's Precision Biology Services, such as spatial biology and liquid biopsy assays, and aid in global commercial expansion outside the US.
Analyst Quicktake: The Orion spatial biology analysis platform was first made available for clinical research in 2020. In September 2021 , RareCyte raised USD 24 million in a Series G funding round to fast-track the platform's commercialization and applications. Arboretum Ventures led the round, which was jointly funded by new and existing investors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.